Verve Therapeutics, a healthcare company focused on improving cardiovascular outcomes through gene-editing technology, has raised $63 million in Series A2 financing.
Verve Therapeutics, a healthcare company focused on improving cardiovascular outcomes through gene-editing technology, has raised $63 million in Series A2 financing.